Intervention Review

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence

  1. Richard P Mattick1,*,
  2. Courtney Breen1,
  3. Jo Kimber1,
  4. Marina Davoli2

Editorial Group: Cochrane Drugs and Alcohol Group

Published Online: 6 FEB 2014

Assessed as up-to-date: 3 DEC 2012

DOI: 10.1002/14651858.CD002207.pub4


How to Cite

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD002207. DOI: 10.1002/14651858.CD002207.pub4.

Author Information

  1. 1

    University of New South Wales, National Drug and Alcohol Research Centre, Sydney, New South Wales, Australia

  2. 2

    Lazio Regional Health Service, Department of Epidemiology, Rome, Italy

*Richard P Mattick, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, New South Wales, 2052, Australia. R.Mattick@unsw.edu.au.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 6 FEB 2014

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Natasa Gisev, Louisa Degenhardt, Sarah Larney, Briony Larance, Amy Gibson, Jo Kimber, Lucy Burns, A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women, Drug and Alcohol Review, 2014, 33, 4
  2. 2
    Silvia Minozzi, Laura Amato, Cristina Bellisario, Marina Davoli, Maintenance treatments for opiate -dependent adolescents, The Cochrane Library,
  3. 3
    Suzanne Nielsen, Louisa Degenhardt, Briony Larance, Linda Gowing, Chyanne Kehler, Nicholas Lintzeris, Opioid agonist treatment for pharmaceutical opioid dependent people, The Cochrane Library,